Form of Exchange AgreementExchange Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This Exchange Agreement and the Terms and Conditions for Exchange of Securities, dated October 2, 2018, attached hereto as Exhibit A (the “Terms and Conditions” and, together with this Exchange Agreement, the “Agreement”) is made as of the date hereof between the Company and the Investor.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 26 day of September, 2018 (the “Effective Date”) by and between Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the “Company”) and Kurt Andrews (the “Executive”).
MASTER SERVICES AGREEMENT Between SAMSUNG BIOLOGICS CO., LTD. and IMMUNOMEDICS, INC.Master Services Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This Master Services Agreement (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between Immunomedics, Inc., a Delaware corporation having its principal place of business at 300 The American Rd, Morris Plains, NJ 07950 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PERSONAL AND CONFIDENTIAL August 23, 2018 Michael Garone Randolph, NJ 07869 Re: Transition AgreementTransition Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
This will confirm the agreement (the “Agreement”) that has been reached with you in connection with the transition and pending separation of your employment from Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the “Company”).
SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT - COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances
This Product Specific Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective Date”) by and between Immunomedics, Inc., a Delaware corporation having its principal place of business at 300 The American Rd, Morris Plains, NJ 07950 (“Client”) and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
